{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:55:27Z","timestamp":1773251727462,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Women undergoing breast cancer (BC) treatment often face side effects that impact their quality of life and adherence. Biomarker tests to predict side effects could improve treatment options and adherence. This study assessed the prevalence of common side effects and women\u2019s preferences for biomarker testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from surveys of patients with BC at University Hospitals Cleveland Medical Center (UHCMC;\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009586) and Penn State Cancer Institute (PSCI;\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009562) were analyzed using descriptive statistics, chi-square, and Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the UHCMC and PSCI cohorts, 53.2% and 60.2% of the women prescribed endocrine therapy experienced joint and musculoskeletal pain (JMSP), respectively, with approximately one third discontinuing or changing treatment for BC. JMSP was associated with a higher mean body mass index (BMI). Over half of the women experienced hot flashes which were associated with younger age and Black race. Of the women receiving chemotherapy, nearly two thirds experienced neuropathy. Approximately one quarter of the respondents reported lymphedema, which as associated with a higher mean BMI, chemotherapy, and Black race. Quality of life was negatively impacted by side effects. Most women who experienced a side effect were more likely to prefer having a predictive test with the exception of women who experienced taxane-induced peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Side effects from BC treatment negatively affect quality of life and could be mitigated if their likelihood was known. Since the majority of BC patients view predictive biomarker testing favorably, future work focusing on treatment side effects is crucial to improve adherence, particularly to endocrine therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-09976-8","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T02:30:19Z","timestamp":1763605819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and predictive testing preferences for breast cancer treatment side effects"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8155-6793","authenticated-orcid":false,"given":"Maura K.","family":"McCall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demesvar","family":"Destin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-7463","authenticated-orcid":false,"given":"Fredrick R.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-2367","authenticated-orcid":false,"given":"Cheryl L.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"1","key":"9976_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"9976_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363\u2013385. https:\/\/doi.org\/10.3322\/caac.21565","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"9976_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"9976_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00520-017-3613-z","volume":"25","author":"D Beckwee","year":"2017","unstructured":"Beckwee D, Leysen L, Meuwis K, Adriaenssens N (2017) Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer 25(5):1673\u20131686. https:\/\/doi.org\/10.1007\/s00520-017-3613-z","journal-title":"Support Care Cancer"},{"issue":"3","key":"9976_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L et al (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108(3):421\u2013426. https:\/\/doi.org\/10.1007\/s10549-007-9612-x","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"9976_CR6","doi-asserted-by":"publisher","first-page":"40558","DOI":"10.18632\/oncotarget.17194","volume":"8","author":"D Hong","year":"2017","unstructured":"Hong D, Bi L, Zhou J, Tong Y, Zhao Q, Chen J et al (2017) Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors. Oncotarget 8(25):40558\u201340567. https:\/\/doi.org\/10.18632\/oncotarget.17194","journal-title":"Oncotarget"},{"issue":"16_suppl","key":"9976_CR7","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/jco.2005.23.16_suppl.8015","volume":"23","author":"L Morales","year":"2005","unstructured":"Morales L, Neven P, Cheroutre E, vande Putte G, Paridaens R (2005) Assessment of hot flashes and clinical correlates in breast cancer patients receiving tamoxifen or third-generation aromatase inhibitors. J Clin Oncol 23(16_suppl):8015. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.8015","journal-title":"J Clin Oncol"},{"issue":"5","key":"9976_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djy136","volume":"111","author":"SB Wheeler","year":"2019","unstructured":"Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L et al (2019) Endocrine therapy nonadherence and discontinuation in Black and White women. J Natl Cancer Inst 111(5):498\u2013508. https:\/\/doi.org\/10.1093\/jnci\/djy136","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9976_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1046\/j.1525-1497.1999.00294.x","volume":"14","author":"JA Grisso","year":"1999","unstructured":"Grisso JA, Freeman EW, Maurin E, Garcia-Espana B, Berlin JA (1999) Racial differences in menopause information and the experience of hot flashes. J Gen Intern Med 14(2):98\u2013103. https:\/\/doi.org\/10.1046\/j.1525-1497.1999.00294.x","journal-title":"J Gen Intern Med"},{"issue":"2","key":"9976_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/toxics3020152","volume":"3","author":"R Velasco","year":"2015","unstructured":"Velasco R, Bruna J (2015) Taxane-induced peripheral neurotoxicity. Toxics 3(2):152\u2013169. https:\/\/doi.org\/10.3390\/toxics3020152","journal-title":"Toxics"},{"issue":"17","key":"9976_CR11","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ejca.2011.06.027","volume":"47","author":"HS Han","year":"2011","unstructured":"Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E et al (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47(17):2537\u20132545. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.027","journal-title":"Eur J Cancer"},{"issue":"1","key":"9976_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","volume":"18","author":"Z Ghoreishi","year":"2018","unstructured":"Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A (2018) Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 18(1):958. https:\/\/doi.org\/10.1186\/s12885-018-4869-5","journal-title":"BMC Cancer"},{"issue":"1","key":"9976_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","volume":"18","author":"Y Tanabe","year":"2013","unstructured":"Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M et al (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132\u2013138. https:\/\/doi.org\/10.1007\/s10147-011-0352-x","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"9976_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2022.1628","volume":"8","author":"G Montagna","year":"2022","unstructured":"Montagna G, Zhang J, Sevilimedu V, Charyn J, Abbate K, Gomez EA et al (2022) Risk factors and racial and ethnic disparities in patients with breast cancer-related lymphedema. JAMA Oncol 8(8):1195\u20131200. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1628","journal-title":"JAMA Oncol"},{"issue":"4","key":"9976_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/gs.2017.11.04","volume":"7","author":"TC Gillespie","year":"2018","unstructured":"Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG (2018) Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg 7(4):379\u2013403. https:\/\/doi.org\/10.21037\/gs.2017.11.04","journal-title":"Gland Surg"},{"issue":"11","key":"9976_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12032-024-02408-3","volume":"41","author":"J Hunley","year":"2024","unstructured":"Hunley J, Doubblestein D, Campione E (2024) Current evidence on patient precautions for reducing breast cancer-related lymphedema manifestation and progression risks. Med Oncol 41(11):262. https:\/\/doi.org\/10.1007\/s12032-024-02408-3","journal-title":"Med Oncol"},{"issue":"2","key":"9976_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"issue":"35","key":"9976_CR18","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1200\/jco.22.02780","volume":"41","author":"JE Knikman","year":"2023","unstructured":"Knikman JE, Wilting TA, Lopez-Yurda M, Henricks LM, Lunenburg C, de Man FM et al (2023) Survival of patients with cancer with dpyd variant alleles and dose-individualized fluoropyrimidine therapy-a matched-pair analysis. J Clin Oncol: Off J Am Soc Clin Oncol 41(35):5411\u20135421. https:\/\/doi.org\/10.1200\/jco.22.02780","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"9976_CR19","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/jco.2004.10.043","volume":"22","author":"JA Meyerhardt","year":"2004","unstructured":"Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS (2004) Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 22(8):1439\u20131446. https:\/\/doi.org\/10.1200\/jco.2004.10.043","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"3","key":"9976_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jgc4.1078","volume":"28","author":"JR Canedo","year":"2019","unstructured":"Canedo JR, Miller ST, Myers HF, Sanderson M (2019) Racial and ethnic differences in knowledge and attitudes about genetic testing in the US: systematic review. J Genet Counsel 28(3):587\u2013601. https:\/\/doi.org\/10.1002\/jgc4.1078","journal-title":"J Genet Counsel"},{"issue":"2","key":"9976_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/jgc4.1653","volume":"32","author":"AS Iltis","year":"2023","unstructured":"Iltis AS, Rolf L, Yaeger L, Goodman MS, DuBois JM (2023) Attitudes and beliefs regarding race-targeted genetic testing of Black people: a systematic review. J Genet Couns 32(2):435\u2013461. https:\/\/doi.org\/10.1002\/jgc4.1653","journal-title":"J Genet Couns"},{"key":"9976_CR22","doi-asserted-by":"publisher","first-page":"104416","DOI":"10.1016\/j.breast.2025.104416","volume":"80","author":"LM Rademaker","year":"2025","unstructured":"Rademaker LM, Gal R, May AM, Batenburg MCT, van der Leij F, Bijlsma RM et al (2025) Side-effects in women treated with adjuvant endocrine therapy for breast cancer. Breast (Edinburgh, Scotland) 80:104416. https:\/\/doi.org\/10.1016\/j.breast.2025.104416","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"4","key":"9976_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/19476035221118417","volume":"13","author":"D Previtali","year":"2022","unstructured":"Previtali D, Boffa A, Di Martino A, Deabate L, Delcogliano M, Filardo G (2022) Recall bias affects pain assessment in knee osteoarthritis: a pilot study. Cartilage 13(4):50\u201358. https:\/\/doi.org\/10.1177\/19476035221118417","journal-title":"Cartilage"},{"issue":"5","key":"9976_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/art.42056","volume":"74","author":"M Gl\u00f8ersen","year":"2022","unstructured":"Gl\u00f8ersen M, Steen Pettersen P, Neogi T, Jafarzadeh SR, Vistnes M, Thudium CS et al (2022) Associations of body mass index with pain and the mediating role of inflammatory biomarkers in people with hand osteoarthritis. Arthritis Rheumatol 74(5):810\u2013817. https:\/\/doi.org\/10.1002\/art.42056","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"9976_CR25","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/art.39707","volume":"68","author":"C Reyes","year":"2016","unstructured":"Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D (2016) Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. Arthritis Rheumatol 68(8):1869\u20131875. https:\/\/doi.org\/10.1002\/art.39707","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"9976_CR26","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/acr.22408","volume":"66","author":"A Gay","year":"2014","unstructured":"Gay A, Culliford D, Leyland K, Arden NK, Bowen CJ (2014) Associations between body mass index and foot joint pain in middle-aged and older women: a longitudinal population-based cohort study. Arthritis Care Res (Hoboken) 66(12):1873\u20131879. https:\/\/doi.org\/10.1002\/acr.22408","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"9976_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/oby.24129","volume":"32","author":"S Wang","year":"2024","unstructured":"Wang S, Shen J, Koh WP, Yuan JM, Gao X, Peng Y et al (2024) Comparison of race- and ethnicity-specific BMI cutoffs for categorizing obesity severity: a multicountry prospective cohort study. Obesity 32(10):1958\u20131966. https:\/\/doi.org\/10.1002\/oby.24129","journal-title":"Obesity"},{"key":"9976_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082601","author":"A Morga","year":"2025","unstructured":"Morga A, Shiozawa A, Todorova L, Ajmera M, Arregui M, Wissinger E (2025) The burden of illness of treatment-induced vasomotor symptoms in individuals with breast cancer: a systematic literature review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14082601","journal-title":"J Clin Med"},{"issue":"6","key":"9976_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/gme.0000000000002349","volume":"31","author":"A Kochersberger","year":"2024","unstructured":"Kochersberger A, Coakley A, Millheiser L, Morris JR, Manneh C, Jackson A et al (2024) The association of race, ethnicity, and socioeconomic status on the severity of menopause symptoms: a study of 68,864 women. Menopause 31(6):476\u2013483. https:\/\/doi.org\/10.1097\/gme.0000000000002349","journal-title":"Menopause"},{"key":"9976_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104739","volume":"211","author":"N Nguyen-Hoang","year":"2025","unstructured":"Nguyen-Hoang N, Nazzal M, Schneider BP, Trivedi MS, Hertz DL (2025) Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy. Crit Rev Oncol Hematol 211:104739. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104739","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"9976_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2021.1856367","volume":"17","author":"DL Hertz","year":"2021","unstructured":"Hertz DL (2021) Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. Expert Opin Drug Metab Toxicol 17(2):227\u2013239. https:\/\/doi.org\/10.1080\/17425255.2021.1856367","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"25","key":"9976_CR32","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO.2012.41.9564","volume":"30","author":"JJ Griggs","year":"2012","unstructured":"Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK et al (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 30(25):3058\u20133064. https:\/\/doi.org\/10.1200\/JCO.2012.41.9564","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"31","key":"9976_CR33","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1200\/JCO.2012.44.2863","volume":"30","author":"JH Beumer","year":"2012","unstructured":"Beumer JH, Chu E, Salamone SJ (2012) Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J Clin Oncol\u202f: Off J Am Soc Clin Oncol 30(31):3896\u20133897. https:\/\/doi.org\/10.1200\/JCO.2012.44.2863","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"9976_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-013-2715-7","volume":"142","author":"LS Jammallo","year":"2013","unstructured":"Jammallo LS, Miller CL, Singer M, Horick NK, Skolny MN, Specht MC et al (2013) Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Res Treat 142(1):59\u201367. https:\/\/doi.org\/10.1007\/s10549-013-2715-7","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"9976_CR35","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1245\/s10434-017-5960-x","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC (2017) Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol 24(10):2972\u20132980. https:\/\/doi.org\/10.1245\/s10434-017-5960-x","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"9976_CR36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1007\/s40615-020-00878-5","volume":"8","author":"MK McCall","year":"2021","unstructured":"McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ (2021) Knowledge and attitudes about genetic testing among Black and White women with breast cancer. J Racial Ethn Health Disparities 8(5):1208\u20131216. https:\/\/doi.org\/10.1007\/s40615-020-00878-5","journal-title":"J Racial Ethn Health Disparities"},{"key":"9976_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/pgs-2016-0205","volume":"18","author":"DL Hertz","year":"2017","unstructured":"Hertz DL, Lynn N, Rae JM (2017) Pharmacogenomics germline genetic predictors of aromatase. Pharmacogenomics 18:481\u2013499","journal-title":"Pharmacogenomics"},{"issue":"5","key":"9976_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.21873\/cgp.20461","volume":"21","author":"K Mokbel","year":"2024","unstructured":"Mokbel K, Weedon M, Moye V, Jackson L (2024) Pharmacogenetics of toxicities related to endocrine treatment in breast cancer: a systematic review and meta-analysis. Cancer Genomics 21(5):421\u2013438. https:\/\/doi.org\/10.21873\/cgp.20461","journal-title":"Cancer Genomics"},{"issue":"5","key":"9976_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","volume":"103","author":"MP Goetz","year":"2018","unstructured":"Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther 103(5):770\u2013777. https:\/\/doi.org\/10.1002\/cpt.1007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09976-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:26Z","timestamp":1765949546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09976-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9976"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09976-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The University Hospitals Institutional Review Board approved the\u00a0protocol\u00a0for the UHCMC cohort parent study\u00a0and this study. The protocol number is 02\u201305-11. The PSCI protocol was approved by the Penn State University IRB STUDY00024191. Participant informed consent was obtained\/verified within REDCap\u00ae by completing the anonymous survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants in the UHCMC study provided their informed consent prior to any data collection. All participants for the PSCI study provided their informed consent prior to any data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1095"}}